Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -108.70% and 6.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?